Rani Therapeutics Holdings, Inc..
RANI.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Rani Therapeutics Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing novel, non-invasive drug delivery solutions. Their primary technology is the RaniPill capsule, an ingestible robotic pill that delivers drugs directly into the small intestine, potentially impro...Show More
Better Health for All
20
Rani Therapeutics' core business is dedicated to developing novel, non-invasive drug delivery solutions, specifically the RaniPill capsule, for conditions such as acromegaly and neuroendocrine tumors.
1
This technology aims to improve bioavailability and patient compliance for biologics typically administered via injection, representing an exceptional health benefit.
2
The company conducted a Phase 1 clinical trial in healthy volunteers in 2019, reporting no serious adverse events.
3
This indicates strong ethical conduct in its initial clinical trials, with a focus on safety and transparent reporting of early-stage results.
Fair Money & Economic Opportunity
0
Rani Therapeutics is a biopharmaceutical company focused on drug delivery solutions, not a financial institution.
1
The provided articles discuss the company's financial performance, corporate debt, and product development, but offer no evidence related to consumer lending, financial services, or initiatives for economic opportunity for underserved populations. Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value are scored as 0, indicating that the company's core business does not involve financial services or products relevant to these metrics.
Fair Pay & Worker Respect
10
Rani Therapeutics has an employee rating of 3.9 out of 5 stars, based on 27 reviews, indicating approximately 78% engagement.
1
No specific regulatory actions, violations, fines, or compliance issues related to labor laws or human rights are mentioned in the provided articles.
2
Employee reviews highlight concerns such as multiple waves of layoffs, disorganization, continuously changing project directions, high administrative workload, and bad management.
3
Positive feedback from employees includes mentions of amazing people, plentiful snacks, unlimited PTO, and a flexible work environment.
4
Fair Trade & Ethical Sourcing
0
No specific, attributable evidence was found in the provided articles for Rani Therapeutics Holdings, Inc. regarding any of the KPIs for Fair Trade & Ethical Sourcing. Articles containing policy details were explicitly attributed to other companies (PotlatchDeltic and Cencora), and one article stated that relevant data was not available for Rani Therapeutics Holdings, Inc.
1
Honest & Fair Business
0
Rani Therapeutics implemented corporate governance changes effective December 31, 2025, which were approved on November 24, 2025.
1
These changes include reducing Class B common stock voting power from ten votes per share to one, eliminating the ability of stockholders to act by written consent, and removing provisions related to a classified board of directors.
2
The company also terminated a Tax Receivable Agreement with InCube Labs, LLC, dated August 3, 2021, without requiring any tax benefit or early termination payments.
3
Additionally, two directors resigned from the board, and two new directors were appointed.
4
Kind to Animals
40
Rani Therapeutics used 4 canine models in a preclinical study for the successful oral delivery of a monoclonal antibody.
1
Additionally, two preclinical studies involving canine subjects were conducted for teriparatide.
2
No War, No Weapons
0
No specific evidence was found in the provided articles regarding Rani Therapeutics Holdings, Inc.'s involvement in arms manufacturing, military contracts, dual-use technology, sales to sanctioned regimes, or any peacebuilding or disarmament initiatives. The articles either focus on the company's core biopharmaceutical business and drug delivery technology or discuss general defense industry spending without mentioning Rani Therapeutics. Therefore, no KPIs could be scored based on the provided information.
Planet-Friendly Business
-20
The company's annual reports and corporate updates do not explicitly mention any environmental compliance violations, fines, or regulatory actions.
1
While regulatory compliance requirements are detailed, no specific issues are summarized, indicating a record of zero reported violations.
2
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles regarding Rani Therapeutics Holdings, Inc.'s performance on any of the KPIs related to 'Respect for Cultures & Communities'. The articles either discuss general bioethics principles, global health issues, or are inaccessible (404 errors), and none provide company-specific information on partnerships, community investment, cultural incidents, protocols, employment, grievance mechanisms, FPIC, governance, cultural preservation, procurement, supplier diversity, cultural site protection, social license, charitable giving, community funds, language inclusivity, incident response, or cultural training.
Safe & Smart Tech
0
No specific, measurable evidence was found in the provided articles to assess Rani Therapeutics Holdings, Inc. against any of the 'Safe & Smart Tech' KPIs. The articles did not contain information regarding data breaches, cybersecurity investment, privacy certifications, AI ethics, security training, encryption implementation, data minimization practices (including retention periods), user data control mechanisms, authentication security, vulnerability management, bug bounty programs, privacy by design integration, security testing coverage, regulatory compliance status, algorithmic harm remediation, or digital rights advocacy. While the company's privacy policy outlines data collection practices and general safeguards, it lacks the quantitative details and specific actions required by the rubric for scoring.
1
Zero Waste & Sustainable Products
0
No information is available regarding Rani Therapeutics Holdings, Inc.'s performance across any of the 'Zero Waste & Sustainable Products' KPIs.
1
The provided article focuses exclusively on the company's RaniPill® Capsule technology, its functionality, and clinical trial results, without addressing waste management, sustainability, or environmental impact.
2